Get the Stockscreener App
205.55
0.50%
1.03
After Hours:
205.01
-0.54
-0.26%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $205.55, with a volume of 2.50M.
It is up +0.50% in the last 24 hours and up +117.49% over the past month.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
See More
Previous Close:
$204.52
Open:
$205.64
24h Volume:
2.50M
Relative Volume:
0.41
Market Cap:
$318.66B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
62.69
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
+6.49%
1M Performance:
+117.49%
6M Performance:
+163.73%
1Y Performance:
+176.09%
1-Day Range:
$204.09
$206.71
1-Week Range:
$187.06
$206.71
52-Week Range:
$61.24
$206.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Krilogy Financial LLC Takes $731,000 Position in AstraZeneca PLC $AZN - MarketBeat
Cookson Peirce & Co. Inc. Invests $1.05 Million in AstraZeneca PLC $AZN - MarketBeat
Advisors Asset Management Inc. Acquires 8,453 Shares of AstraZeneca PLC $AZN - MarketBeat
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory - Yahoo Finance
Shore Capital lowers AstraZeneca to 'hold' - Sharecast.com
Published on: 2026-02-13 16:14:39 - mfd.ru
AstraZeneca's (AZN) Breztri Aerosphere Shows Promising Results i - GuruFocus
AstraZeneca's BREZTRI Shows Significant Asthma Improvement in Phase III Trials - Intellectia AI
Caprock Group LLC Takes $3.10 Million Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Announces BrePREMIUM Trial Results - Intellectia AI
AstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials - marketscreener.com
AstraZeneca Earnings: Strong Finish to Year, and Busy Schedule of Data Readouts Ahead - Morningstar Canada
AstraZeneca PLC (LON:AZN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review (UPDATED) - Benzinga
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
6,649 Shares in AstraZeneca PLC $AZN Acquired by Westover Capital Advisors LLC - MarketBeat
Here’s What Lifted AstraZeneca PLC (AZN) in Q4 - Insider Monkey
Madison Asset Management LLC Trims Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca - Benzinga
Kangtai Drops Plan for China Vaccine JV With AstraZeneca - Citeline News & Insights
AstraZeneca awards $3.4 million to US nonprofits to expand healthcare access - MSN
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's What Happened - MarketBeat
China charges former AstraZeneca regional head Leon Wang - marketscreener.com
AstraZeneca (AZN) Faces Legal Challenges in China - GuruFocus
Former AstraZeneca regional head charged in China (AZN:NYSE) - Seeking Alpha
AstraZeneca And Daiichi Sankyo Stack The Odds For Datroway’s Lung Cancer Bets - Citeline News & Insights
How AstraZeneca shot for the moon — and hit - Financial Times
China charges former AstraZeneca executive Leon Wang - marketscreener.com
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive
AstraZeneca's ex-chief in China formally charged with insurance fraud - The Edge Malaysia
Chinese Authorities Charge AstraZeneca's Ex-China Business Head - marketscreener.com
Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline - Yahoo Finance UK
AstraZeneca PLC (NYSE:AZN) Q4 2025 Earnings Call Transcript - Insider Monkey
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US - marketscreener.com
$3.4M for 47 local groups tackling care gaps, nutrition and lung disease - Stock Titan
China charges former AstraZeneca executive - Financial Times
AstraZeneca PLC (NYSE:AZN) Q4 2025 earnings call transcript - MSN
What's Driving the Market Sentiment Around AstraZeneca PLC? - Benzinga
AstraZeneca PLC (NASDAQ:AZN) Sees Significant Drop in Short Interest - MarketBeat
AstraZeneca PLC $AZN Holdings Boosted by ABC Arbitrage SA - MarketBeat
AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials - Clinical Trials Arena
Astrazeneca re-doses $80bn annual sales goal - marketscreener.com
AstraZeneca (AZN) Projects Moderate Revenue Growth by FY26 - GuruFocus
AstraZeneca - Britannica
AstraZeneca stock hits all-time high at 194.18 USD By Investing.com - Investing.com Nigeria
AstraZeneca Earnings Call Highlights Growth And Pipeline - TipRanks
AstraZeneca Q4 Earnings Call Highlights - Yahoo Finance
AstraZeneca: Q4 Earnings AnalysisTicks The Boxes, Upgrading To Buy (AZN) - Seeking Alpha
AstraZeneca Q4 and FY 2025 slides: 8% revenue growth, strategic investments for 2030 By Investing.com - Investing.com South Africa
AstraZeneca's GLP-1 pill succeeds in two mid-stage trials - TechTarget
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):